TNGX - Tango Therapeutics, Inc.
Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET
Tango Therapeutics (NASDAQ: TNGX - Get Free Report) and Alumis (NASDAQ: ALMS - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk. Risk and Volatility Tango Therapeutics has a beta of
Alnylam Pharmaceuticals (NASDAQ: ALNY - Get Free Report) and Tango Therapeutics (NASDAQ: TNGX - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk. Analyst Recommendations This is a breakdown of current
Tidal Investments LLC acquired a new stake in Tango Therapeutics, Inc. (NASDAQ: TNGX) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 55,384 shares of the company's stock, valued at approximately $1,731,000. A number of other hedge funds and other institutional
Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock?
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango Therapeutics or the Company) today announced that, effective September 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 146,500 shares of its common stock and 40,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan.
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 AM EDT.
Algert Global LLC boosted its holdings in shares of Tango Therapeutics, Inc. (NASDAQ: TNGX) by 86.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 271,570 shares of the company's stock after purchasing an additional 125,930 shares during the
Bank of America Corp DE trimmed its stake in Tango Therapeutics, Inc. (NASDAQ: TNGX) by 31.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 327,144 shares of the company's stock after selling 150,918 shares during the quarter. Bank of
ADAR1 Capital Management LLC bought a new position in shares of Tango Therapeutics, Inc. (NASDAQ: TNGX) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 76,761 shares of the company's stock, valued at approximately $2,400,000. A number of other institutional investors have also made
Vopimetostat's combination with daraxonrasib has produced an unusually strong early pancreatic-cancer signal, but the evidence still comes from a very small, previously treated cohort. A planned front-line Phase 3 trial could substantially expand the opportunity, although its final design, timing, and regulatory path remain unsettled. Additional combination, lung-cancer, and CNS readouts should show whether TNGX is building a broader PRMT5 franchise or relying too heavily on one early dataset.
Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.
BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Dr. Barbara Weber, the Executive Chairman of the Board of Directors of Tango Therapeutics, will be stepping down in connection with other pursuits.
Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.
Shares of Tango Therapeutics, Inc. (NASDAQ: TNGX - Get Free Report) have received an average rating of "Moderate Buy" from the sixteen research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and thirteen have given a buy
The average of price targets set by Wall Street analysts indicates a potential upside of 49.5% in Tango Therapeutics (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Tango Therapeutics, Inc. (NASDAQ: TNGX - Get Free Report)'s share price shot up 6.1% on Friday. The stock traded as high as $29.25 and last traded at $29.3360. 316,615 shares changed hands during trading, a decline of 91% from the average daily volume of 3,701,445 shares. The stock had previously closed at $27.64. Analyst Upgrades
Tango Therapeutics' strong 2026 rally reflects promising clinical progress, but its premium valuation puts upcoming study results at the center of the next move.
TNGX is advancing precision oncology with MTAP-targeted therapies and 2026 data readouts that could test its clinical and commercial potential.
Tango Therapeutics enters a pivotal phase as vopimetostat drives its investment case, with 2026 clinical updates set to test its focused oncology pipeline.